CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

abrocitinib

Last Updated: June 2, 2021
Result type: Reports
Project Number: SR0686-000
Product Line: Reimbursement Review

Generic Name: abrocitinib

Brand Name: TBC

Manufacturer: Pfizer Canada ULC

Therapeutic Area: Atopic dermatitis, moderate to severe

Indications: ​For the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, including the relief of pruritus, who have had an inadequate response to prescribed topical therapy or for whom these treatments are not advisable. Abrocitinib can be used with or without medicated topical therapies for atopic dermatitis.

Manufacturer Requested Reimbursement Criteria1: As per the label: For the treatment of patients aged 12 years and older with moderate-to-severe AD, including the relief of pruritus, who have had an inadequate response to prescribed topical therapy or for whom these treatments are not advisable. Abrocitinib can be used with or without medicated topical therapies for atopic dermatitis.

Submission Type: Initial

NOC Status at Filing: Pre NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open March 26, 2021
Call for patient/clinician input closed May 21, 2021
Clarification:

- Patient input submission received from the Canadian Skin Patient Alliance (CSPA) & Eczéma Québec and the Eczema Society of Canada

Submission received April 26, 2021
Submission accepted May 10, 2021
Review initiated May 11, 2021
Draft CADTH review report(s) provided to sponsor for comment July 26, 2021
Deadline for sponsors comments August 05, 2021
CADTH responses on draft review report(s) provided to sponsor September 10, 2021
Expert committee meeting (initial) September 22, 2021
Draft recommendation issued to sponsor October 04, 2021
To
October 06, 2021